John Hunter Peel Alexander, MD

Professor of Medicine
Member in the Duke Clinical Research Institute
Campus mail 200 Morris Street, Durham, NC 27701
Phone (919) 668-8955
Email address john.h.alexander@duke.edu

John H. Alexander, MD, MHS is a cardiologist and Professor of Medicine in the Department of Medicine, Division of Cardiology at Duke University School of Medicine, as well as the Vice Chief, Clinical Research in the Division of Cardiology. He is the Director of Cardiovascular Research at the Duke Clinical Research Institute where he oversees a large group of clinical research faculty and a broad portfolio of cardiovascular clinical trials and observational clinical research programs. He is a member of the American Society of Clinical Investigation.

Dr. Alexander’s clinical interests are in acute and general cardiovascular disease, valvular heart disease, and echocardiology. His research is focused on the translation of novel therapeutic concepts into clinical data through clinical trials, specifically on the therapeutics of acute coronary syndromes, chronic coronary artery disease, and cardiac surgery and on novel methodological approaches to clinical trials. He was on the Executive Committee of the ARISTOTLE trial of apixaban in patients with atrial fibrillation and was the Principal Investigator of the APPRAISE-2 trial of apixaban in patients with acute coronary syndromes.

Dr. Alexander has published extensively and has served as the principal investigator of numerous multicenter clinical trials. He currently serves as the co-chair of the Clinical Trial Transformation Initiative (CTTI).

Education and Training

  • Fellow in Cardiology, Medicine, Duke University, 1996 - 2000
  • Medical Resident, Medicine, Children's Hospital, Boston, 1993 - 1996
  • M.D., University of Pennsylvania, 1993

Publications

Sharma, Abhinav, Emil Hagström, Daniel M. Wojdyla, Megan L. Neely, Robert A. Harrington, Lars Wallentin, John H. Alexander, Shaun G. Goodman, Renato D. Lopes, and Renato D. Apixaban for Prevention of Acute Ischemic Safety Events APPRAISE-2 Steering Committee and Investigators. “Clinical consequences of bleeding among individuals with a recent acute coronary syndrome: Insights from the APPRAISE-2 trial..” Am Heart J 215 (September 2019): 106–13. https://doi.org/10.1016/j.ahj.2019.05.004.

PMID
31310855
Full Text

Goldstein, Sarah A., Jennifer Green, Kurt Huber, Daniel M. Wojdyla, Renato D. Lopes, John H. Alexander, Dragos Vinereanu, Lars Wallentin, Christopher B. Granger, and Sana M. Al-Khatib. “Characteristics and Outcomes of Atrial Fibrillation in Patients With Thyroid Disease (from the ARISTOTLE Trial)..” Am J Cardiol, August 7, 2019. https://doi.org/10.1016/j.amjcard.2019.07.046.

PMID
31474328
Full Text

Guimarães, Patricia O., Renato D. Lopes, John H. Alexander, Laine Thomas, Anne S. Hellkamp, Ziad Hijazi, Elaine M. Hylek, et al. “International normalized ratio control and subsequent clinical outcomes in patients with atrial fibrillation using warfarin..” J Thromb Thrombolysis 48, no. 1 (July 2019): 27–34. https://doi.org/10.1007/s11239-019-01858-1.

PMID
30972712
Full Text

Harskamp, Ralf E., John H. Alexander, and Renato D. Lopes. “Navigating the treacherous waters of antithrombotic therapies in patients with atrial fibrillation and coronary artery disease: Lessons from AUGUSTUS..” Eur J Intern Med 65 (July 2019): 4–5. https://doi.org/10.1016/j.ejim.2019.05.018.

PMID
31128977
Full Text

Diepen, Sean van, Rajendra H. Mehta, Jeffrey D. Leimberger, Shaun G. Goodman, Stephen Fremes, Rachael Jankowich, Matthias Heringlake, et al. “Levosimendan in patients with reduced left ventricular function undergoing isolated coronary or valve surgery..” J Thorac Cardiovasc Surg, June 21, 2019. https://doi.org/10.1016/j.jtcvs.2019.06.020.

PMID
31358329
Full Text

Lopes, Renato D., Hwanhee Hong, Ralf E. Harskamp, Deepak L. Bhatt, Roxana Mehran, Christopher P. Cannon, Christopher B. Granger, et al. “Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis of Randomized Controlled Trials..” Jama Cardiol, June 19, 2019. https://doi.org/10.1001/jamacardio.2019.1880.

PMID
31215979
Full Text

DeRose, Joseph J., Donna M. Mancini, Helena L. Chang, Michael Argenziano, François Dagenais, Gorav Ailawadi, Louis P. Perrault, et al. “Pacemaker Implantation After Mitral Valve Surgery With Atrial Fibrillation Ablation..” J Am Coll Cardiol 73, no. 19 (May 21, 2019): 2427–35. https://doi.org/10.1016/j.jacc.2019.02.062.

PMID
31097163
Full Text

Alexander, Karen P., and John H. Alexander. “Safe and Effective Anticoagulation: What Does Drug Concentration Add?.” J Am Geriatr Soc, May 21, 2019. https://doi.org/10.1111/jgs.15981.

PMID
31112619
Full Text

Hohnloser, Stefan H., Marat Fudim, John H. Alexander, Daniel M. Wojdyla, Justin A. Ezekowitz, Michael Hanna, Dan Atar, et al. “Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight..” Circulation 139, no. 20 (May 14, 2019): 2292–2300. https://doi.org/10.1161/CIRCULATIONAHA.118.037955.

PMID
30773022
Full Text

Guimarães, Patricia O., Sean D. Pokorney, Renato D. Lopes, Daniel M. Wojdyla, Bernard J. Gersh, Anna Giczewska, Anthony Carnicelli, et al. “Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial..” Clin Cardiol 42, no. 5 (May 2019): 568–71. https://doi.org/10.1002/clc.23178.

PMID
30907005
Full Text

Pages